BACKGROUND: Associations between transforming growth factor (TGF)-β1 polymorphisms and hepatocellular carcinoma (HCC) risk remained controversial. Therefore, we performed this meta-analysis to investigate these associations. METHODS: We searched Pubmed, EMBASE, Chinese National Knowledge Infrastructure (CNKI), and Wanfang databases for studies before March 2013. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to calculate the strength of association. RESULTS: A total of 14 studies were included in this meta-analysis. TGF-β1 +869C/T polymorphism was significantly associated with HCC risk (OR=1.74, 95% CI: 1.22-2.47, p=0.002). In addition, a significant association between -509C/T polymorphism and HCC risk was observed (OR=1.40, 95% CI: 1.15-1.70, p=0.0007). Furthermore, significant associations between these polymorphisms and HCC risk were found in Asians and population-based studies. CONCLUSIONS: Our meta-analysis suggested that the TGF-β1 +869C/T and -509C/T polymorphisms may be risk factors for developing HCC.
BACKGROUND: Associations between transforming growth factor (TGF)-β1 polymorphisms and hepatocellular carcinoma (HCC) risk remained controversial. Therefore, we performed this meta-analysis to investigate these associations. METHODS: We searched Pubmed, EMBASE, Chinese National Knowledge Infrastructure (CNKI), and Wanfang databases for studies before March 2013. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to calculate the strength of association. RESULTS: A total of 14 studies were included in this meta-analysis. TGF-β1 +869C/T polymorphism was significantly associated with HCC risk (OR=1.74, 95% CI: 1.22-2.47, p=0.002). In addition, a significant association between -509C/T polymorphism and HCC risk was observed (OR=1.40, 95% CI: 1.15-1.70, p=0.0007). Furthermore, significant associations between these polymorphisms and HCC risk were found in Asians and population-based studies. CONCLUSIONS: Our meta-analysis suggested that the TGF-β1 +869C/T and -509C/T polymorphisms may be risk factors for developing HCC.
Authors: N Ito; S Kawata; S Tamura; K Takaishi; Y Shirai; S Kiso; I Yabuuchi; Y Matsuda; M Nishioka; S Tarui Journal: Cancer Res Date: 1991-08-01 Impact factor: 12.701
Authors: Shelli M Morris; Ji Yeon Baek; Amanda Koszarek; Samornmas Kanngurn; Sue E Knoblaugh; William M Grady Journal: Hepatology Date: 2011-12-06 Impact factor: 17.425
Authors: D J Grainger; K Heathcote; M Chiano; H Snieder; P R Kemp; J C Metcalfe; N D Carter; T D Spector Journal: Hum Mol Genet Date: 1999-01 Impact factor: 6.150
Authors: F van Zijl; M Mair; A Csiszar; D Schneller; G Zulehner; H Huber; R Eferl; H Beug; H Dolznig; W Mikulits Journal: Oncogene Date: 2009-08-31 Impact factor: 9.867
Authors: Oh Sang Kwon; Suk Ho Song; Ki Tak Ju; Moon Gi Chung; Dong Kyun Park; Sun Suk Kim; Yeon Suk Kim; Yang Suh Koo; Yu Kyung Kim; Duck Joo Choi; Ju Hyun Kim; You Jin Hwang; Kwan Soo Byun; Chang Hong Lee Journal: Korean J Gastroenterol Date: 2003-09